NEWS
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Savara Inc. (Nasdaq: SVRA) announced that a new episode of The Balancing Act® on Lifetime TV's Behind the Mystery™ series is featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP). The episode, sponsored by Savara, focuses on an aPAP patient's diagnostic journey and includes insights from Dr. Bruce Trapnell, the International Coordinating Investigator for Savara's IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution in aPAP.
The episode aims to educate viewers about aPAP's symptoms and diagnosis, highlighting the lack of approved treatments in the US and Europe. Savara's CEO, Matt Pauls, emphasized the company's commitment to the aPAP community and their goal of providing an effective therapy. Savara expects to complete submission of the Biologics License Application (BLA) for molgramostim in aPAP with the FDA in the first half of 2025.
The episode aims to educate viewers about aPAP's symptoms and diagnosis, highlighting the lack of approved treatments in the US and Europe. Savara's CEO, Matt Pauls, emphasized the company's commitment to the aPAP community and their goal of providing an effective therapy. Savara expects to complete submission of the Biologics License Application (BLA) for molgramostim in aPAP with the FDA in the first half of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2217Followers
104Following
21KVisitors
Follow